Prognostic Assessment in Patients with Indolent B-Cell Lymphomas
نویسندگان
چکیده
منابع مشابه
Prognostic Assessment in Patients with Indolent B-Cell Lymphomas
Follicular lymphoma (FL) is an indolent lymphoma with long median survival. Many studies have been performed to build up prognostic scores potentially useful to identify patients with poorer outcome. In 2004, an international consortium coordinated by the International Follicular Lymphoma Prognostic Factor project was established and a new prognostic study was launched (FLIPI2) using progressio...
متن کاملIndolent B-cell non-Hodgkin's lymphomas.
The indolent B-cell non-Hodgkin's lymphomas are a diverse group of disorders that differ markedly with respect to presenting features and natural history. This article reviews entities that have generally been encompassed under the category of indolent lymphomas in various classifications, including the Working Formulation, although many were not specifically identified or labeled as separate e...
متن کاملTransformation of indolent B-cell lymphomas.
Histologic transformation (HT) to an aggressive lymphoma is a well-described event in the natural history and clinical course of patients with so-called indolent lymphomas. This phenomenon has been studied most extensively in patients with follicular lymphoma and subsequent transformation to a diffuse large B-cell lymphoma, with little literature on HT in nonfollicular lymphomas. Despite a cons...
متن کاملXIV. The pathology of transformation of indolent B cell lymphomas.
This paper will describe the histopathologic features of transformation that occur during the course of indolent B cell lymphomas. The clinical and molecular features that underlie this transformation event are described in detail in the two accompanying papers in this series (see Gribben and Rossi, respectively). The focus will be on follicular lymphoma (FL), although reference will be made to...
متن کاملCombination of Lenalidomide and Rituximab Overcomes Rituximab Resistance in Patients with Indolent B-cell and Mantle Cell Lymphomas.
PURPOSE Lenalidomide, an immunomodulatory agent that enhances antibody-dependent cell-mediated cytotoxicity, has the potential to synergize with rituximab, an anti-CD20 mAb. We hypothesized that the addition of lenalidomide to rituximab would improve clinical outcomes in patients with B-cell lymphomas who were previously rituximab resistant, defined as no response to or progression of lymphoma ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: The Scientific World Journal
سال: 2012
ISSN: 1537-744X
DOI: 10.1100/2012/107892